Health Condition 1: L639- Alopecia areata, unspecified
Conditions
Interventions
Intervention1: tofacitinib: Oral tofacitinib 5 mg twice daily for 4 months
Control Intervention1: Oral methylprednisolone 32 mg on two consecutive days per week: Oral methylprednisolone 32 mg on two c
Sponsors
Institute of Medical Sciences BHU
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed cases of alopecia areata with severity of alopecia tool (SALT) score of 10 % or over. 2. Age: 18 to 65 years 3. Patients not taking systemic drug in last 1 month and topical treatment in last 15 days. - All participants who give consent for the study
Exclusion criteria
Exclusion criteria: 1. Patients having history or active tuberculosis. 2. Patients with Pregnancy and lactating mother. 3. Patients with uncontrolled renal, hepatic, hematological or heart disease. 4. Patients with diabetes mellitus and hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in severity of alopecia tool (SALT) score by 90%Timepoint: Reduction in severity of alopecia tool (SALT) score by 90% which will assessed monthly for 4 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in severity of alopecia tool (SALT) score by 50% & reduction in severity of alopecia tool (SALT) score by 100%Timepoint: Reduction in severity of alopecia tool (SALT) score by 50% & reduction in severity of alopecia tool (SALT) score by 100% which will be assessed monthly for 4 months. | — |
Countries
India
Contacts
Public ContactDr Bhagirath Bhakar
Institute of Medical Sciences Banaras Hindu University
Outcome results
None listed